Colgate-Palmolive stock snapshot after recent performance

Colgate-Palmolive (CL) has drawn investor attention after a 1-month return of 7.04%, alongside a 3-month decline of 6.27%. This combination is prompting closer inspection of how its fundamentals line up with recent price action.

At a share price of US$90.61, Colgate-Palmolive’s recent 7.04% 1-month share price return contrasts with a 6.27% decline over 3 months, while its 5-year total shareholder return of 23.72% points to steadier long term compounding. This suggests recent momentum has cooled rather than firmly reversed the longer record.

If this kind of performance has you considering what else might be worth a look, it could be a good moment to broaden your search and uncover 20 top founder-led companies

So with Colgate-Palmolive trading at US$90.61 and an indicated 24.53% intrinsic discount, is the stock still underappreciated by the market, or are expectations for future growth already fully priced in?

Most Popular Narrative: 6.3% Undervalued

With Colgate-Palmolive at $90.61 versus a narrative fair value of $96.68 based on a 6.98% discount rate, the current setup revolves around how effectively management executes its 2030 plan on growth and margins.

Expansion and premiumization of core oral care lines like Colgate Total, coupled with the roll out of complementary products across 75 markets, are set to capture increased value from emerging middle class consumers and rising health/hygiene awareness globally, supporting top line organic sales acceleration and improved pricing power.

Want to see what is behind that confidence in earnings and cash flow? The narrative leans on higher profitability, steadier revenue compounding, and a richer future earnings multiple tied to that 2030 roadmap.

Result: Fair Value of $96.68 (UNDERVALUED)

However, persistent input cost pressure and softer demand in key markets such as North America, Brazil, China, and India could challenge the earnings and valuation narrative.

Another View: Multiples Paint a Tougher Picture

The earlier fair value narrative and SWS DCF result suggest Colgate-Palmolive at US$90.61 is trading below an estimated future cash flow value of US$120.06. Yet on earnings, the stock looks expensive, with a P/E of 34.7x versus a fair ratio of 23.8x, a peer average of 21.5x, and a global household products average of 16.7x. That gap implies valuation risk if sentiment cools or growth assumptions are nudged lower. Which signal do you think holds more weight right now?

Next Steps

The mix of upside potential and clear risks in this story is hard to ignore, so it is worth checking the numbers yourself and acting while the current setup is still fresh in the market. You can start with a closer look at the 3 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you risk missing out on other opportunities that might fit your goals even better, so widen your search before you move on.

• Target potential upside by scanning a focused list of 48 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their metrics.
• Strengthen your income focus by reviewing 10 dividend fortresses that aim to pair higher yields with resilience through different market conditions.
• Prioritize resilience by checking out 65 resilient stocks with low risk scores that score well on financial health and business risk, so you can decide where you want steadier exposure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.